REDDIE Consortium Meets in Split for 3rd Progress Meeting

From 26–28 April 2026, partners of the REDDIE project gathered in Split, Croatia, for the consortium’s 3rd Progress Meeting, hosted by RISE - Research and Innovation Services at the Technology Park Split.

The meeting brought together partners from across Europe to review progress, exchange insights, and define the next steps in advancing the project’s mission to improve the use of real-world evidence (RWE) in diabetes research and decision-making.

Over the course of two days of discussions, partners provided updates on progress across all work packages, with a particular focus on bridging the gap between clinical trials and real-world care. REDDIE has shown that while treatments often have similar relative effects as seen in clinical trials, their real-world impact can differ significantly, especially in broader, lower-risk patient populations. This has important implications for clinical practice and health policy.

The consortium also presented progress in developing practical frameworks to support the use of real-world data in regulatory and health technology assessment (HTA) decision-making. These approaches aim to ensure that RWE is applied in a transparent, robust, and meaningful way, ultimately strengthening evidence-based healthcare decisions.

A key strength of REDDIE lies in its multi-country collaboration. By analysing data from several European national registries, partners demonstrated how diversity in datasets can provide better insights into treatment performance in real-world settings, rather than being a limitation.

Patient-centred research remains at the heart of the project. Through the active involvement of the Patient Advisory Committee, REDDIE continues to ensure that its outputs are relevant, accessible, and aligned with the needs of people living with diabetes.

Beyond scientific and technical progress, the meeting also focused on future opportunities. REDDIE has laid important groundwork for continued innovation by developing tools, datasets, and collaborations that will support upcoming research initiatives, including new proposals in digital health, real-world data, and cardiometabolic disease.

The 3rd Progress Meeting marked a key milestone for REDDIE, reinforcing the consortium’s shared commitment to advancing the integration of real-world and synthetic data into clinical research and healthcare decision-making.